JP2021535153A5 - - Google Patents
Info
- Publication number
- JP2021535153A5 JP2021535153A5 JP2021510864A JP2021510864A JP2021535153A5 JP 2021535153 A5 JP2021535153 A5 JP 2021535153A5 JP 2021510864 A JP2021510864 A JP 2021510864A JP 2021510864 A JP2021510864 A JP 2021510864A JP 2021535153 A5 JP2021535153 A5 JP 2021535153A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- enpp1
- seq
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024165046A JP2025000736A (ja) | 2018-08-31 | 2024-09-24 | Ｅｎｐｐ１ポリペプチドおよびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725607P | 2018-08-31 | 2018-08-31 | |
| US62/725,607 | 2018-08-31 | ||
| US201962830247P | 2019-04-05 | 2019-04-05 | |
| US62/830,247 | 2019-04-05 | ||
| PCT/US2019/049243 WO2020047520A1 (en) | 2018-08-31 | 2019-08-31 | Enpp1 polypeptides and methods of using same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024165046A Division JP2025000736A (ja) | 2018-08-31 | 2024-09-24 | Ｅｎｐｐ１ポリペプチドおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021535153A JP2021535153A (ja) | 2021-12-16 |
| JP2021535153A5 true JP2021535153A5 (https=) | 2022-09-05 |
Family
ID=69643272
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510864A Pending JP2021535153A (ja) | 2018-08-31 | 2019-08-31 | Ｅｎｐｐ１ポリペプチドおよびその使用方法 |
| JP2024165046A Pending JP2025000736A (ja) | 2018-08-31 | 2024-09-24 | Ｅｎｐｐ１ポリペプチドおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024165046A Pending JP2025000736A (ja) | 2018-08-31 | 2024-09-24 | Ｅｎｐｐ１ポリペプチドおよびその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12344868B2 (https=) |
| EP (1) | EP3844280A4 (https=) |
| JP (2) | JP2021535153A (https=) |
| CN (2) | CN120383683A (https=) |
| AU (1) | AU2019327572B2 (https=) |
| CA (1) | CA3110498A1 (https=) |
| WO (1) | WO2020047520A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3126839A1 (en) * | 2019-01-18 | 2020-07-23 | Inozyme Pharma, Inc. | Treatment of diseases involving deficiency of enpp1 or enpp3 |
| KR20230047334A (ko) * | 2020-05-27 | 2023-04-07 | 이노자임 파마, 인코포레이티드 | 혈관 평활근 세포 증식을 억제하기 위한 조성물 및 방법 |
| WO2021252549A1 (en) * | 2020-06-09 | 2021-12-16 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
| CA3246877A1 (en) * | 2022-03-30 | 2023-10-05 | Yale University | METHOD AND COMPOSITIONS FOR THE TREATMENT, ALLEVIATION AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH) |
| CN116769718A (zh) * | 2023-04-21 | 2023-09-19 | 南京逸微健华生物科技有限公司 | 一种工程化细胞外囊泡及用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| WO1995019570A1 (en) | 1994-01-14 | 1995-07-20 | Genentech, Inc. | Antagonists to insulin receptor tyrosine kinase inhibitor |
| US6043056A (en) | 1998-11-06 | 2000-03-28 | Incyte Pharmaceuticals, Inc. | Cell surface glycoproteins |
| US6521645B2 (en) | 2000-11-20 | 2003-02-18 | The University Of Kansas Medical Center | Methods for the treatment and prevention of urinary stone disease |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7888372B2 (en) | 2001-03-23 | 2011-02-15 | National Institutes Of Health (Nih) | Compositions and methods for modulating bone mineral deposition |
| US20020183276A1 (en) | 2001-03-23 | 2002-12-05 | Burnham Institute | Compositions and methods for modulating bone mineral deposition |
| US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
| AU2002324700A1 (en) | 2001-08-14 | 2003-03-03 | Bayer Ag | Nucleic acid and amino acid sequences involved in pain |
| JP4200100B2 (ja) | 2001-11-07 | 2008-12-24 | アジェンシス，インコーポレイテッド | 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質 |
| WO2003072593A2 (en) | 2002-02-21 | 2003-09-04 | University Of Virginia Patent Foundation | Bone targeting peptides |
| JP5199077B2 (ja) | 2005-06-10 | 2013-05-15 | アルタス ファーマシューティカルズ インコーポレイテッド | シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法 |
| WO2008105911A2 (en) | 2006-08-02 | 2008-09-04 | Altus Pharmaceuticals Inc. | Crystallized oxalate decarboxylase and methods of use |
| US20080273206A1 (en) | 2007-04-23 | 2008-11-06 | University Of South Carolina | Biomimetic Mineralization Method and System |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| US8846603B2 (en) | 2010-03-12 | 2014-09-30 | Synageva Biopharma Corp. | NPP1 fusion proteins |
| RU2601154C2 (ru) | 2011-03-11 | 2016-10-27 | Синаджива Байофарма Корп | Гибридные белки npp1 |
| WO2014126965A2 (en) | 2013-02-13 | 2014-08-21 | Yale University | Compositions and methods for treating pathological calcification and ossification |
| EP2970940B1 (en) | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Mrna therapeutic compositions and use to treat diseases and disorders |
| ES2708565T3 (es) | 2013-03-15 | 2019-04-10 | Atyr Pharma Inc | Conjugados de Fc-histidil-ARNt sintetasa |
| AU2014305843B2 (en) | 2013-08-09 | 2019-08-29 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
| EP3967755B1 (en) | 2014-12-19 | 2024-03-27 | Inozyme Pharma, Inc. | Soluble npp1 for use in a method for treating pseudoxanthoma elasticum |
| EP4414028A3 (en) | 2015-05-19 | 2024-11-27 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| EP3377105A4 (en) | 2015-11-20 | 2019-04-24 | Yale University | COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| CA3032467A1 (en) | 2016-08-05 | 2018-02-08 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| US20190367579A1 (en) * | 2017-02-27 | 2019-12-05 | Shattuck Labs, Inc. | Tigit- and light-based chimeric proteins |
| AU2019267545A1 (en) | 2018-05-08 | 2020-11-26 | Yale University | Compositions and methods for reducing progression of nephrolithiasis |
-
2019
- 2019-08-31 CN CN202510521331.8A patent/CN120383683A/zh active Pending
- 2019-08-31 JP JP2021510864A patent/JP2021535153A/ja active Pending
- 2019-08-31 CA CA3110498A patent/CA3110498A1/en active Pending
- 2019-08-31 CN CN201980070064.XA patent/CN112930397B/zh active Active
- 2019-08-31 US US17/271,018 patent/US12344868B2/en active Active
- 2019-08-31 EP EP19855284.6A patent/EP3844280A4/en active Pending
- 2019-08-31 AU AU2019327572A patent/AU2019327572B2/en active Active
- 2019-08-31 WO PCT/US2019/049243 patent/WO2020047520A1/en not_active Ceased
-
2024
- 2024-09-24 JP JP2024165046A patent/JP2025000736A/ja active Pending
-
2025
- 2025-06-02 US US19/225,265 patent/US20260049294A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021535153A5 (https=) | ||
| AU778939B2 (en) | Expression and export of anti-obesity proteins as Fc fusion proteins | |
| ES2714406T3 (es) | Composiciones que comprenden fosfatasa alcalina y / o péptido natriurético y procedimientos de uso de las mismas | |
| JP6571735B2 (ja) | 止血を調節する組成物および方法 | |
| CN103974716B (zh) | 凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途 | |
| CN104774269B (zh) | 改良型人凝血因子FVII-Fc融合蛋白及其制备方法与用途 | |
| JP5833448B2 (ja) | セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用 | |
| JP6514893B2 (ja) | 止血を調節するための組成物および方法 | |
| CN103159860B (zh) | 重组组织型纤溶酶原激活剂及其制备方法与用途 | |
| US9644197B2 (en) | Fusion protein having factor VII activity | |
| NZ521437A (en) | Integrin antagonists suitable as inhibitors of angiogenesis | |
| JP6251677B2 (ja) | 新規の突然変異組織プラスミノーゲン活性化因子及びその使用 | |
| JP2022527557A5 (https=) | ||
| JP2023529892A5 (https=) | ||
| US5656484A (en) | Protein S deletion variants deficient in C4BP binding activity but having APC cofactor activity compositions and therapeutic methods | |
| WO1993022447A1 (fr) | Nouveau polypeptide | |
| RU2021132096A (ru) | Enpp1 полипептиды и способы их применения | |
| AU2012375257B2 (en) | Osteoprotegerin derived composition and use thereof | |
| CN1408875A (zh) | 表达TNF受体:IgG1 Fc嵌合蛋白的DNA型Semliki森林脑炎病毒载体 | |
| CN118667797A (zh) | 一种重组酸性α-葡萄糖苷酶及其用途 | |
| RU2024129908A (ru) | Способ и композиции для лечения, облегчения и/или предупреждения диффузного идиопатического скелетного гиперостоза (dish) |